Aligos Therapeutics: Funding, Investors & Team (Sep 2026)
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Aligos Therapeutics has raised $281M across 3 funding rounds on record, the most recent an undisclosed round of $105M announced in Feb 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aligos Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2025.
Aligos Therapeutics Funding Rounds
Aligos Therapeutics raised $83.6M in a Post-IPO Equity announced in Jul 2021.
2.3 years later, an undisclosed round of $92.0M was announced in Oct 2023.
1.3 years later, an undisclosed round of $105M was announced in Feb 2025.
Aligos Therapeutics Founders and Leadership Team
Contact details for the Aligos Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Aligos Therapeutics Funding Compared to Other Biotechnology Startups
Aligos Therapeutics' latest round of $105M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aligos Therapeutics in Biotechnology and San Francisco
Companies Similar to Aligos Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Aligos Therapeutics Funding FAQs
What does Aligos Therapeutics do?
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
How much funding has Aligos Therapeutics raised?
Aligos Therapeutics has raised $281M across 3 rounds on record. The most recent is an undisclosed round of $105M announced in Feb 2025.
When did Aligos Therapeutics last raise funding?
Aligos Therapeutics' most recent funding round on record is an undisclosed round of $105M, announced in Feb 2025.
Who is the CEO of Aligos Therapeutics?
Lawrence Blatt is listed as CEO at Aligos Therapeutics.
Where is Aligos Therapeutics headquartered?
Aligos Therapeutics is based in San Francisco, California, United States.
How many employees does Aligos Therapeutics have?
Aligos Therapeutics is in the 101-250 employee band.
How does Aligos Therapeutics' funding compare to other Biotechnology startups?
Aligos Therapeutics' latest round of $105M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Aligos Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aligos Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.